CPC A61K 39/092 (2013.01) [A61K 39/0002 (2013.01); A61K 39/002 (2013.01); A61K 39/0003 (2013.01); A61K 39/0005 (2013.01); A61K 39/012 (2013.01); A61K 39/0258 (2013.01); A61K 39/05 (2013.01); A61K 39/08 (2013.01); A61K 39/085 (2013.01); A61K 39/118 (2013.01); A61K 39/12 (2013.01); A61K 39/39 (2013.01); G01N 33/56944 (2013.01); A61K 2039/552 (2013.01); A61K 2039/55561 (2013.01); A61K 2039/55566 (2013.01); A61K 2039/55572 (2013.01); A61K 2039/55577 (2013.01); A61K 2039/55583 (2013.01); G01N 2333/315 (2013.01); G01N 2469/10 (2013.01); Y02A 50/30 (2018.01)] | 7 Claims |
1. A vaccine composition comprising a Rhipicephalus microplus antigen and an adjuvant, said adjuvant being selected from the group consisting of:
a) an aqueous adjuvant comprising an immunostimulatory oligonucleotide, a saponin, a sterol, a quaternary amine, a polyacrylic polymer, and a glycolipid; and
b) an oil-based adjuvant, comprising an oily phase present in the amount of at least 45% v/v of the vaccine composition and comprising an immunostimulatory oligonucleotide and a polycationic carrier, wherein said vaccine composition is a water-in-oil emulsion.
|